Please login to the form below

Not currently logged in
Email:
Password:

insulin

This page shows the latest insulin news and features for those working in and with pharma, biotech and healthcare.

Sanofi sells European generics to Advent for $2.4bn

Sanofi sells European generics to Advent for $2.4bn

Sanofi is in the midst of a shakedown of its business prompted by a decline in sales of its diabetes blockbuster Lantus (insulin glargine) and the failure of some other products

Latest news

More from news
Approximately 72 fully matching, plus 457 partially matching documents found.

Latest Intelligence

  • Managing medication non-adherence Managing medication non-adherence

    One Drop, the digital diabetes mHealth app, has recently shown that AC1 levels are reduced by 1% in people using the app to track their insulin, glucose, activity and food.

  • When science is not enough When science is not enough

    Destructive. Given that Pfizer had to pull its powder-based insulin drug Exubera after it had returned just $13m in sales from an 11-year $2.8bn development project, it seems

  • Deal Watch May 2016 Deal Watch May 2016

    Similarly, Bristol-Myers Squibb has called time on its deal with Biocon for IN-105/Tregopil [oral insulin].

  • Harnessing commercial innovation Harnessing commercial innovation

    We needed to ensure that people were safe. Then we needed to ensure that our insulin was made available to people in Japan. ... From our own point of view, we need to ensure that our devices have connectivity - you need to be able to store and transfer

  • Deal Watch January 2016 Deal Watch January 2016

    It was a big news month for Sanofi, also in the news for terminating its licensing deal with MannKind for Afrezza (inhaled insulin).

More from intelligence
Approximately 0 fully matching, plus 33 partially matching documents found.

Latest appointments

  • Emperra appoints Bent Johnsen as CEO Emperra appoints Bent Johnsen as CEO

    Johnsen’s expertise lies in the health care sector and he has held several executive leadership positions within the field of diabetes working for insulin manufacturing companies as well as other

  • Novo Nordisk appoints Liz Skrbkova Novo Nordisk appoints Liz Skrbkova

    She will move from the company's UK team to take up a role in Søborg, Denmark, where she will focus on the company's modern insulin and device portfolio.

  • Adocia names senior members of new US subsidiary Adocia names senior members of new US subsidiary

    He joins from Halozyme Pharmaceuticals, where he held the position of executive medical director and worked on the ultra-rapid insulin programme. ... He most recently served as VP of commercial at Halozyme, also on the ultra-rapid insulin programme.

  • JDRF names new CEO JDRF names new CEO

    pancreas to deliver insulin in people with type 1 diabetes.

  • Hanspeter Spek to retire from Sanofi Hanspeter Spek to retire from Sanofi

    During his time at Sanofi, he has helped with the success of several significant products, including bloodthinner Plavix, insulin Lantus and cancer drug Taxotere.

More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Could hackers threaten your health?

    cybersecurity. After being hit by recent discoveries of security flaws in on-the-market insulin pumps, pacemakers, and infusion pumps, cyber security researchers and medical suppliers are even considering a “ Hippocratic

  • Blog: Digital therapeutics: within our reach?

    Clipsulin device: automatically counts and transmits the number of injected doses of insulin to your mobile phone, helping you to keep track of your treatment.

  • CES 2017 – Medical Device Top Picks

    CES 2017 – Medical Device Top Picks. Connected tech was the overriding theme at this year's Consumer Electronics Show in Las Vegas. But among all that consumer gadgetry, there were some great medical devices too. So what are the ones to watch in

  • Pegasus

    Liz Skrbkova - Global Communications Manager, Modern Insulins &Devices, Novo Nordisk Global:. “

  • Research Partnership

    Medical devices and diagnostics. Our experience covers everything from insulin pens to large-scale surgical systems.

More from PMHub
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics